OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-16 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 0.00% 10-K · filed 2024-03-11 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-09 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 0.00% 10-K · filed 2022-02-28 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |